<DOC>
	<DOCNO>NCT01690091</DOCNO>
	<brief_summary>The aim study evaluate effect metformin myocardial function , insulin resistance select metabolic marker patient type 2 diabetes heart failure ( HF+DM+ ) cross-over , randomize , placebo control trial . Hypothesis : Metformin treatment HF+DM+ group lead well myocardial function load tolerance comparison placebo . The degree improvement link select metabolic parameter .</brief_summary>
	<brief_title>Cardioprotective Metabolic Effects Metformin Patients With Heart Failure Diabetes</brief_title>
	<detailed_description>40 patient HF DM without previous diabetes treatment randomize 2 group ( A succession : MET-placebo , B succession : placebo-MET ) - stratify randomization follow parameter weight : HF etiology ( ischemic /non-ischemic ) , diabetes duration , gender , BMI , age , NYHA , smoker/non-smoker ) . After 3 month treatment switch . All participant undergo standardize selection metabolic cardiovascular test ( hyperinsulinemic euglycemic clamp indirect calorimetry , measurement endothelial function , echocardiography , spiroergometry , proton/phosphor MR spectroscopy , adipose tissue biopsy , select cytokine plasma adipose tissue begin end intervention period ( 3 time total ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. chronic heart failure define follow criterion ( must include ) : diagnosis HF know least 6 month medical history hospitalization cardiac decompensation need parenteral therapy congestion Xray finding swell low extremity stable drug therapy least 1 month treatment diuretic ( thiazide furosemide ) LVEF 50 % 2. presence diabetes define : diagnosis treatment type 2 diabetes medical history screen blood sample : value HbA1c ( accord IFCC ) ≥ 4.8 % + fasting glucose ≥ 7.0 mmol / l venous plasma value HbA1c ≥ 4.8 % ( accord IFCC ) + random blood glucose ≥ 11.1 mmol/l venous plasma OGTT blood glucose level 120 min ≥ 11.1 mmol/l OGTT indicate case positivity one criterion ( fast glucose + HbA1c HbA1c + random blood glucose ) treatment diabetes diet woman men age 4070 year body mass index ( kg/m2 ) range 2035 range HbA1c 46,5 % IFCC sign informed consent 1. plan cardiac intervention study affect function heart ( revascularization include PCI , heart surgery , implantation pacemaker , RF ablation ; urgent candidate OTS 2. metabolic disease , include : 1 type diabetes , decompensated thyreopathy ( Note : patient hypothyroidism stable substitution ( last 3 month ) normal TSH level may participate study 3. treatment insulin PAD one month recruitment ( patient temporarily treat insulin hospitalization may participate study ) 4. pregnancy ( positive βHCG test ) , breast feeding , try become pregnant 5. clinically significant anemia hemoglobin 100 g/l 6. renal insufficiency eGF 0.7 ml/s 7. atrial fibrillation present screen test 8. presence medical condition , occur physical examination , laboratory test , ECG , include pulmonary , neurological inflammatory disease , would consider examiner distort consistency data</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>metformin</keyword>
	<keyword>insulin resistance</keyword>
</DOC>